Page last updated: 2024-10-26

donepezil and Diarrhea

donepezil has been researched along with Diarrhea in 14 studies

Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.

Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.

Research Excerpts

ExcerptRelevanceReference
"The objective of this 10-week, randomized, double-blind, placebo-controlled multicenter study was to assess the efficacy and safety of donepezil for the treatment of cognitive dysfunction exhibited by children with Down syndrome (DS)."9.14Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. ( Escobar, L; Heller, JH; Kishnani, PS; Lott, I; McRae, T; Richardson, S; Spiridigliozzi, GA; Zhang, R, 2010)
"The objective of this 10-week, randomized, double-blind, placebo-controlled multicenter study was to assess the efficacy and safety of donepezil for the treatment of cognitive dysfunction exhibited by children with Down syndrome (DS)."5.14Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. ( Escobar, L; Heller, JH; Kishnani, PS; Lott, I; McRae, T; Richardson, S; Spiridigliozzi, GA; Zhang, R, 2010)
"(1) Donepezil can reduce memory loss, dry mouth, and constipation in nongeriatric affective patients, but may trigger mania; and (2) long-term follow-up will reveal the predictive value for dementia of donepezil's memory restoration in nongeriatric subjects."5.09Donepezil for psychotropic-induced memory loss. ( Comas-Díaz, L; Jacobsen, FM, 1999)
" This study evaluated the effects of pretreatment with the oral cholinesterase inhibitor and anti-Alzheimer's agent, donepezil (Aricept) on the hypokinetic, hypothermic and diarrhea-inducing effects of the irreversible long-acting cholinesterase inhibitor, diisopropylfluorophosphate (DFP) in adult Sprague-Dawley rats."3.73Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: a potential nerve agent treatment. ( Davis, JM; Janowsky, DS; Overstreet, DH, 2005)
" Experiment 1 tested the effects of 5 mg/per day dosage on cognitive and EEG markers at 6-hour, 2-week and 4-week follow-ups."2.76Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers. ( Balsters, JH; Bokde, AL; Brennan, S; Cassidy, SM; Delmonte, S; Fagan, AJ; Galli, A; Kilcullen, SM; Lai, R; Laruelle, M; Lawlor, B; Martin, MP; Meaney, JF; O'Connell, RG; Robertson, IH; Upton, N, 2011)
" Adverse events (AEs) were recorded throughout."2.75Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. ( Doody, RS; Ferris, S; Gao, J; Goldman, R; Murthy, AK; Salloway, S, 2010)
"Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer's Disease Functional Assessment and Change Scale (mean change from baseline score effect size at week 24: donepezil 5 mg/d, -1."2.71Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. ( Black, S; Burns, A; Geldmacher, DS; Hecker, J; Kumar, D; Perdomo, C; Pratt, R; Román, GC; Salloway, S, 2003)
"Donepezil (Aricept) is a highly selective acetylcholinesterase inhibitors with a pharmacokinetic profile allowing once-daily dosing."2.42Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. ( Geldmacher, DS, 2004)
"Donepezil is a synthetic noncovalent reversible inhibitor of acetylcholinesterase (AChE) for the treatment of mild to moderate dementia associated with Alzheimer's disease."2.40Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. ( Shintani, EY; Uchida, KM, 1997)
"The objective was to investigate the frequency of adverse events (AE) as a cause for discontinuation of donepezil treatment for Alzheimer's dementia (DAT) in a geriatric memory unit."1.35[Adverse events causing discontinuation of donepezil for Alzheimer's dementia]. ( Carøe, TK; Moe, C, 2009)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (21.43)18.2507
2000's7 (50.00)29.6817
2010's4 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davoren, JE1
Garnsey, M1
Pettersen, B1
Brodney, MA1
Edgerton, JR1
Fortin, JP1
Grimwood, S1
Harris, AR1
Jenkinson, S1
Kenakin, T1
Lazzaro, JT1
Lee, CW1
Lotarski, SM1
Nottebaum, L1
O'Neil, SV1
Popiolek, M1
Ramsey, S1
Steyn, SJ1
Thorn, CA1
Zhang, L1
Webb, D1
Doody, RS1
Ferris, S1
Salloway, S2
Goldman, R1
Gao, J1
Murthy, AK1
Carøe, TK1
Moe, C1
Kishnani, PS2
Heller, JH2
Spiridigliozzi, GA2
Lott, I1
Escobar, L1
Richardson, S1
Zhang, R1
McRae, T1
Balsters, JH1
O'Connell, RG1
Martin, MP1
Galli, A1
Cassidy, SM1
Kilcullen, SM1
Delmonte, S1
Brennan, S1
Meaney, JF1
Fagan, AJ1
Bokde, AL1
Upton, N1
Lai, R1
Laruelle, M1
Lawlor, B1
Robertson, IH1
Sullivan, JA1
Doraiswamy, PM1
Krishnan, RR1
Black, S1
Román, GC1
Geldmacher, DS2
Hecker, J1
Burns, A1
Perdomo, C1
Kumar, D1
Pratt, R1
Janowsky, DS2
Davis, JM2
Overstreet, DH2
Shintani, EY1
Uchida, KM1
Carrier, L1
Jacobsen, FM1
Comas-Díaz, L1
Lam, W1

Reviews

2 reviews available for donepezil and Diarrhea

ArticleYear
Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.
    Expert review of neurotherapeutics, 2004, Volume: 4, Issue:1

    Topics: Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorder

2004
Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997, Dec-15, Volume: 54, Issue:24

    Topics: Aged; Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Diarrhea; Donepezil; Drug Administrati

1997

Trials

6 trials available for donepezil and Diarrhea

ArticleYear
Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study.
    American journal of Alzheimer's disease and other dementias, 2010, Volume: 25, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Amnesia; Cholinesterase Inhibitors; Cognition Disorders; Diarrhea; D

2010
Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17.
    American journal of medical genetics. Part A, 2010, Volume: 152A, Issue:12

    Topics: Adolescent; Behavior; Caregivers; Child; Cholinesterase Inhibitors; Cognition Disorders; Diarrhea; D

2010
Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers.
    PloS one, 2011, Volume: 6, Issue:9

    Topics: Aged; Analysis of Variance; Cholinesterase Inhibitors; Cognition; Cross-Over Studies; Diarrhea; Done

2011
Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial.
    American journal of medical genetics. Part A, 2003, Jan-15, Volume: 116A, Issue:2

    Topics: Adult; Appetite; Cholinesterase Inhibitors; Diarrhea; Donepezil; Dose-Response Relationship, Drug; D

2003
Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
    Stroke, 2003, Volume: 34, Issue:10

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Cardiovascular System; Cholinesterase Inhibitor

2003
Donepezil for psychotropic-induced memory loss.
    The Journal of clinical psychiatry, 1999, Volume: 60, Issue:10

    Topics: Adult; Ambulatory Care; Cholinesterase Inhibitors; Constipation; Depressive Disorder; Diarrhea; Dizz

1999

Other Studies

6 other studies available for donepezil and Diarrhea

ArticleYear
Design and Synthesis of γ- and δ-Lactam M
    Journal of medicinal chemistry, 2017, 08-10, Volume: 60, Issue:15

    Topics: Allosteric Regulation; Amphetamine; Animals; Ataxia; Diarrhea; Dogs; Donepezil; Drug Design; Female;

2017
[Adverse events causing discontinuation of donepezil for Alzheimer's dementia].
    Ugeskrift for laeger, 2009, Dec-07, Volume: 171, Issue:50

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Appetite; Cholinesterase Inhibitors; Diarrhea; Donepezil

2009
Antagonism of anticholinesterase (DFP) toxicity by donepezil plus scopolamine: a preliminary study.
    Pharmacology, biochemistry, and behavior, 2004, Volume: 77, Issue:2

    Topics: Animals; Behavior, Animal; Body Temperature; Cholinesterase Inhibitors; Diarrhea; Donepezil; Drug In

2004
Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: a potential nerve agent treatment.
    Pharmacology, biochemistry, and behavior, 2005, Volume: 81, Issue:4

    Topics: Animals; Behavior, Animal; Body Temperature; Cholinesterase Inhibitors; Diarrhea; Donepezil; Hypokin

2005
Donepezil and paroxetine: possible drug interaction.
    Journal of the American Geriatrics Society, 1999, Volume: 47, Issue:8

    Topics: Aged; Aggression; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Confusion; Diar

1999
Pharmacological treatment of cognitive deficits in Alzheimer's disease.
    The Medical journal of Australia, 2002, Mar-18, Volume: 176, Issue:6

    Topics: Alzheimer Disease; Diarrhea; Donepezil; Humans; Indans; Nausea; Nootropic Agents; Piperidines; Vomit

2002